Yeasts as important agents of onychomycosis: In vitro activity of propolis against yeasts isolated from patients with nail infection

Journal of Alternative and Complementary Medicine

Volumn 19, Issue 1, 2013, Pages 57-62

  Khosravi, Ali Reza ^a   Shokri, Hojjatollah ^b   Nikaein, Donya ^a   Mansouri, Parvin ^c   Erfanmanesh, Ahmad ^d   Chalangari, Reza ^c   Katalin, Martis ^c  

^a UNIVERSITY OF TEHRAN   (Iran)

^b UNIVERSITY OF MAZANDARAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PROPOLIS;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA TROPICALIS; CONTROLLED STUDY; DERMATOPHYTE; FEMALE; FUNGUS ISOLATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALASSEZIA GLOBOSA; MALASSEZIA PACHYDERMATIS; MALE; MINIMUM INHIBITORY CONCENTRATION; NAIL INFECTION; NONHUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; APITHERAPY; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FLUCONAZOLE; HUMANS; INFANT; MIDDLE AGED; ONYCHOMYCOSIS; PROPOLIS; PROSPECTIVE STUDIES; SPECIES SPECIFICITY; YEASTS; YOUNG ADULT;

EID: 84872432164     PISSN: 10755535     EISSN: 15577708     Source Type: Journal    
DOI: 10.1089/acm.2011.0722     Document Type: Article

References (46)

1. Yenisehirli G, Bulut Y, Sezer E, Gunday E. Onychomycosis infections in the middle Black Sea region, Turkey. Int J Dermatol 2009;48:956-959.
2. Murray SC, Dawber RP. Onychomycosis of toenails: orthopaedic and podiatric considerations. Australas J Dermatol 2002;43:105-112. (Pubitemid 34533962)
3. Migdley G, Moore MK, Cookk JC, Phan QG. Mycology of nail disorders. J Am Acad Derm 1994;31:68-74.
4. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P, Odom R, Aly R, Pariser D, Zaiac M, Rebell G, Lesher J, Gerlach B, Ponce-De-Leon GF, Ghannoum A, Warner J, Isham N, Elewski B. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility pattern. J Am Acad Dermato 2002;43:641-648.
5. Araú jo AJG, Bastos OMP, Souza MAJ, Oliveira JC. Onychomycosis caused by emergent fungi: clinical analysis, diagnosis and revision. An Bras Dermatol 2003;78:445-455. (Pubitemid 37070060)
6. Gupta AK, Ryder JE, Summerbell RC. Onychomycosis: classification and diagnosis. J Drugs Dermatol 2004b;3: 51-56.
7. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-410. (Pubitemid 36461317)
8. Dorko E, Jautova J, Tkacikova L, Wantrubova A. The frequency of Candida species in onychomycosis. Folia Microbiol 2002;47:727-731. (Pubitemid 135695790)
9. Mujica MT, Finquelievich JL, Jewtuchowicz V, Iovannitti CA. Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999-2001. Rev Argent Microbiol 2004;36:107-112. (Pubitemid 39482197)
10. Chi CC, Wang SH, Chou MC. The causative pathogens of onychomycosis in southern Taiwan. Mycoses 2005;48: 413-420.
11. Bramono K, Budimulja U. Epidemiology of onychomycosis in Indonesia: data obtained from three individual studies. Jpn J Med Mycol 2005;46:171-176. (Pubitemid 41302362)
12. Romano C, Gianni C, Difonzo EM. Retrospective study of onychomycosis in Italy: 1985-2000. Mycoses 2005;48:42-44. (Pubitemid 40255400)
13. Effendy I, Lecha M, de Chauvin M, Di Chiacchio N, Baran R. European onychomycosis observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol 2005;19:8-12. (Pubitemid 41726923)
14. Nada H, Mokhtar M, Saad S. Yeast infections as a cause of nail disease in the western province of Saudi Arabia. Egypt J Med Lab Sci 2005;14:1-7.
15. Ilkit M. Onychomycosis in Adana, Turkey: a 5-year study. Int J Dermatol 2005;44:851-854. (Pubitemid 41535703)
16. Ioannidou DJ, Maraki S, Krasagakis SK, Tosca A, Tselentis Y. The epidemiology of onychomycoses in Crete, Greece, between 1992 and 2001. J Eur Acad Dermatol Venereol 2006; 20:170-174. (Pubitemid 43740517)
17. Sanjiv A, Shalini M, Charoo H. Etiological agents of onychomycosis from a tertiary care hospital in Central Delhi, India. Indian J Fundam Appl Life Sci 2011;1:11-14.
18. Bruggemann RJ, Alffenaar JW, Blijlevens NM. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441-1458.
19. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005;19:21-29. (Pubitemid 40268136)
20. Imhof M, Lipovac M, Kurz CH, Barta J, Verhoeven HC, Huber JC. Propolis solution for the treatment of chronic vaginitis. Int J Gynecol Obstet 2005;89:127-132. (Pubitemid 40585611)
21. Oliveira ACP, Longhini R, Franco SL, Svidzinski TIE. Antifungal activity of propolis extract against yeasts isolated from onychomycosis lesions. Memó rias do Instituto Oswaldo Cruz 2006;101:493-497. (Pubitemid 44285790)
22. Yarfani R, Khosravi AR, Shokri H. The antifungal activity of Iranian propolis samples against fluconazole-resistant Candida albicans strains isolated from HIV + patients with oropharyngeal candidiasis. J ApiProduct ApiMedical Sci 2010; 2:160-165.
23. Shokri H, Khosravi AR, Yalfani R. Antifungal efficacy of propolis against fluconazole-resistant Candida glabrata isolates obtained from women with recurrent vulvovaginal candidiasis. Int J Gynecol Obstet 2011;114:158-159.
24. Khosravi AR, Yarahmadi S, Baiat M, Shokri H, Pourkabireh M. Factors affecting the prevalence of yeasts in the oral cavity of patients with diabetes mellitus. J Mycol Méd 2008; 18:83-88.
25. Naeini AR, Nazeri M, Shokri H. Antifungal activity of Zataria multiflora, Pelargonium graveolens and Cuminum cyminum essential oils towards three species of Malassezia isolated from patients with pityriasis versicolor. J Mycol Méd 2011;21:87-91.
26. Clinical Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Approved Standard, M27-A2. Wayne, PA: Clinical Laboratory Standards Institute, 2002.
27. Consolaro MEL, Albertoni TAA, Svidzinski AE, Peralata RM, Svidzinski TIE. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia 2005;159:501-507. (Pubitemid 40876666)
28. Kam KM, Au WF, Wong PY, Cheung MM. Onychomycosis in Hong Kong. Int J Dermatol 1997;36:757-761. (Pubitemid 27497330)
29. Kiraz M, Yegenoglu Y, Erturan Z, Ang O. The epidemiology of onychomycosis in Istanbul, Turkey. Mycoses 1999;42: 323-329.
30. Perea S, Ramos MJ, Garau M, Gonzalez A, Noriega AR, del Palacio A. Prevalence and risk factors of Tinea unguium and Tinea pedis in the general population in Spain. J Clin Microbiol 2000;38:3226-3230.
31. Lopes JO, Alves SH, Mari CR, Oliveira LT, Brum LM, Westphalen JB, Furian FW, Altermann MJ. A ten year survey of onychomycosis in the central region of the Rio Grande do Sul, Brazil. Rev Inst Med Trop Sao Paulo 1999; 41:147-149.
32. Clayton Y. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol 1992;17:37-40.
33. Ellabib MS, Agaj M, Khalifa Z, Kavanagh K. Yeasts of the genus Candida are the dominant cause of onychomycosis in Libyan women but not men: results of a 2-year surveillance study. Br J Dermatol 2002;146:1038-1041. (Pubitemid 34779485)
34. Brilhante RSN, Cordeiro RA, Medrano DJA, Rocha MFG, Monteiro AJ, Cavalcante CSP, Meireles TEF, Sidrim JJC. Onychomycosis in Ceará (Northeast Brazil): epidemiological and laboratory aspects. Mem Inst Oswaldo Cruz 2002;100: 131-135. (Pubitemid 40745431)
35. Silva V, Moreno GA, Zaror L, de Oliveira E, Fischman O. Isolation of Malassezia spp. furfur from patient with onychomycosis. J Med Vet Mycol 1997;35:73-74. (Pubitemid 27085388)
36. Chowdhary A, Randhawa HS, Sharma S, Brandt ME, Kumar S. Malassezia furfur in a case of onychomycosis: colonizer or etiologic agent? Med Mycol 2005;43:87-90. (Pubitemid 40192605)
37. Ota C, Unterkircher C, Fantinato V, Shimizu MT. Antifungal activity of propolis on different species of Candida. Mycoses 2001;44:375-378. (Pubitemid 34015719)
38. Dalben-Dota KF, Consolaro MLC, Svidzinski TIE, Bruschi ML. Antifungal activity of Brazilian propolis microparticles against yeasts isolated from vulvovaginal candidiasis. Evid Based Complement Alternat Med 2011;2011:1-8.
39. Dalben-Dota KF, Faria MG, Bruschi ML, Pelloso SM, Lopes- Consolaro ME, Svidzinski TI. Antifungal activity of propolis extract against yeasts isolated from vaginal exudates. J Altern Complement Med 2010;16:285-290.
40. Koç AN, Silici S, Kasap F, Ho?rmet-Oz HT, Mavus-Buldu H, Ercal BD. Antifungal activity of the honeybee products against Candida spp. and Trichosporon spp. J Med Food 2011; 14:128-134.
41. Lilenbaum W, Barbosa AV. Avaliaçao da atividade antimicrobiana da pró polis perante Malassezia pachydermatis in vitro. Rev Bras Med Vet 1995;16:248-251.
42. Cardoso RL, Maboni F, Machado G, Alves SH, de Vargas AC. Antimicrobial activity of propolis extract against Staphylococcus coagulase positive and Malassezia pachydermatis of canine otitis. Vet Microbiol 2010;142:432-434.
43. Silici S, Koc AN, Mistik S. Comparison of in vitro activities of antifungal drugs and propolis against yeasts isolated from patients with superficial mycoses. AnnMicrobiol 2007;57:269-272. (Pubitemid 47112674)
44. Herrera CL, Alvear M, Barrientos L, Montenegro G, Salazar A. The antifungal effect of six commercial extracts of Chilean propolis on Candida spp. Cien Inv Agr 2010;37:75-84.
45. Kartal M, Yildiz S, Kaya S, Kurucu S, Topcu G. Antimicrobial activity of propolis samples from two different regions of Anatolia. J Ethnopharmacol 2003;86:69-73. (Pubitemid 36398661)
46. Sommez S, Kirilmaz L, Yucesoy M, Yucel B, Ylmaz B. The effect of bee propolis on oral pathogens and human gingival fibroblast. J Ethnopharmacol 2005;102:371-376. (Pubitemid 41571843)